Number of shares and voting rights of Innate Pharma as at february 7, 2017
10 Février 2017 - 7:00AM
NUMBER OF SHARES
AND VOTING RIGHTS OF Innate Pharma AS AT FEBRUARY 7, 2017
Marseille, February 10, 2017
Pursuant to the article L. 233-8
II of the French « Code de Commerce » and the article
223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter,
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 -
IPH) releases its total number of shares outstanding as well as its
voting rights as at February 7, 2017:
Total number of shares
outstanding: 54,010,754
Total number of theoretical voting rights (1): 54,010,754
Total number of exercisable voting rights (2): 53,992,179
(1) The total
number of theoretical voting rights (or "gross" voting rights) is
used as the basis for calculating the crossing of shareholding
thresholds. In accordance with Article 223-11 of the AMF General
Regulation, this number is calculated on the basis of all shares to
which voting rights are attached, including shares whose voting
rights have been suspended.
(2) The total
number of exercisable voting rights (or "net" voting rights) is
calculated without taking into account the shares held in treasury
by the Company, with suspended voting rights. It is released so as
to ensure that the market is adequately informed, in accordance
with the recommendation made by the AMF on July 17, 2007.
About Innate
Pharma:
Innate Pharma S.A. is a
clinical-stage biotechnology company with a focus on discovering
and developing first-in-class therapeutic antibodies that harness
the innate immune system to improve cancer treatment and clinical
outcomes for patients.
Innate Pharma specializes in
immuno-oncology, a new therapeutic field that is changing cancer
treatment by mobilizing the power of the body's immune system to
recognize and kill cancer cells.
The Company's aim is to become a
commercial stage biopharmaceutical company in the area of
immunotherapy and focused on serious unmet medical needs in cancer.
Innate Pharma has pioneered the discovery and development of
checkpoint inhibitors to activate the innate immune system. Innate
Pharma's innovative approach has resulted in three first-in-class,
clinical-stage antibodies targeting natural killer cell receptors
that may address a broad range of solid and hematological cancer
indications as well as additional preclinical product candidates
and technologies. Targeting receptors involved in innate immunity
also creates opportunities for the Company to develop therapies for
inflammatory diseases.
The Company's expertise and
understanding of natural killer cell biology have enabled it to
enter into major alliances with leaders in the biopharmaceutical
industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk
A/S and Sanofi.
Based in Marseille, France, Innate
Pharma has more than 150 employees and is listed on Euronext
Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
Practical
Information about Innate Pharma shares:
ISIN code
Ticker code |
FR0010331421
IPH |
Disclaimer:
This press release contains
certain forward-looking statements. Although the company believes
its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF,
which is available on the AMF website (http://www.amf-france.org)
or on Innate Pharma's website.
This press release and the
information contained herein do not constitute an offer to sell or
a solicitation of an offer to buy or subscribe to shares in Innate
Pharma in any country.
For additional
information, please contact:
Innate Pharma
Laure-Hélène Mercier
Chief Financial Officer
Tel.: +33 (0)4 30 30 30 87
investors@innate-pharma.com
|
International Media and Investor
Relations
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Hendrik Thys
Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com |
ATCG Press (France)
Marie Puvieux
Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com
|
|
PR in English
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: INNATE PHARMA via Globenewswire
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024